Nasdaq ardx.

Find the latest Institutional Holdings data for Ardelyx, Inc. Common Stock (ARDX) at Nasdaq.com.How much is Ardelyx stock worth today? ( NASDAQ: ARDX) Ardelyx currently has 232,137,709 outstanding shares. With Ardelyx stock trading at $4.33 per share, the total value of Ardelyx stock (market capitalization) is $1.01B. Ardelyx stock was originally listed at a price of $14.11 in Jun 19, 2014.Ardelyx Inc stock price (ARDX) NASDAQ: ARDX. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Ardelyx Inc stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting.WALTHAM, Mass., May 01, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...

For example, the Ardelyx, Inc. (NASDAQ:ARDX) share price had more than doubled in just one year - up 226%. And in the last month, the share price has gained …Jul 21, 2021 · And so to Ardelyx ( ARDX ). Shares were scraping the bottom in Tuesday’s trading with a massive 74% drop after the company announced it had received a letter from the FDA which suggests approval ... Ardelyx (ARDX) Company Description: Ardelyx, Inc. is a biopharmaceutical company, which engages in the research, development and commercialization of medicine for the treatment of renal diseases.

WALTHAM, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has approved XPHOZAH ...Dec 13, 2022 · Ardelyx, Inc. (NASDAQ:ARDX) is a Waltham, Massachusetts-based biotech company founded in 2007. The company has the distinction of developing and commercializing the first-in-class therapeutic for ...

Oct 31, 2023 · Ardelyx (ARDX) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.11 per share. This compares to loss of $0.14 per share a year ago. These ... Nov 28, 2023 · Ardelyx Inc (NASDAQ:ARDX) trade information. Instantly ARDX has showed a red trend with a performance of -1.60% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 4.49 on Monday, 11/27/23 increased the stock’s daily price by 4.01%. 25 thg 8, 2023 ... Cantor Fitzgerald, by way of analyst Louise Chen, upgraded Ardelyx to “overweight” in light of a very strong potential win. The analysts expect ...Analysts' Revenue Estimates For Ardelyx, Inc. (NASDAQ:ARDX) Are Surging Higher Dec 02. Ardelyx Announces Launching of IBSRELA® Second Quarter of 2022 Dec 01. Insider notifies of intention to sell stock Nov 19. Third quarter 2021 earnings released: US$0.42 loss per share (vs US$0.20 loss in 3Q 2020)Ardelyx, Inc. Common Stock (ARDX). Nasdaq Listed ...

On this news, the Company’s stock price fell $0.70, or 13.4%, to close at $4.51 per share on May 26, 2021, on unusually heavy trading volume.

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.

The US FDA has accepted an NDA resubmission from Ardelyx ( NASDAQ: ARDX) for Xphozah (tenapanor) as a chronic kidney disease treatment. The agency determined the application is subject a a class 2 ...Oct 9, 2023 · According to Seeking Alpha data, Ardelyx's market cap of $864.92M shows decent market confidence, especially with its robust revenue growth forecasts: 2023 at $100.6M, and 2024 at $175.84M ... Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical ...Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical ...About Latest Pre-Market Trades. Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day.The stock of Ardelyx Inc (NASDAQ: ARDX) has decreased by 0.00 when compared to last closing price of 3.56.Despite this, the company has seen a loss of -11.44% in its stock price over the last five trading days. The Motley Fool reported 2023-10-31 that Ardelyx delivered a surprise profit thanks to strong sales of Ibsrela, its first FDA-approved ...ARDX ARDX AFTER HOURS QUOTE ARDX LATEST AFTER HOURS TRADES. ... Add symbols now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing stocks, funds and ETFs, ...

Ardelyx Inc (NASDAQ: ARDX) Ardelyx is a biotech penny stock which already has a successful product on the market . Ibsrela (tenapanor) is a drug that was introduced by the company in March 2022. It is used …WALTHAM, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...Webull offers ARDX Ent Holdg (ARDX) historical stock prices, in-depth market analysis, NASDAQ: ARDX real-time stock quote data, in-depth charts, free ARDX ...Xencor Inc. 18.74. +0.01. +0.05%. Get Ardelyx Inc (ARDX:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.Aug 28, 2023 · Ardelyx, Inc. (NASDAQ:ARDX) focuses on treatments for gastrointestinal system and kidney diseases. Its latest analyst share coverage came from Cantor Fitzgerald which upgraded the share rating to ... Ardelyx, Inc. (NASDAQ:ARDX) has gained about 353% over the past 12 months. As of the end of the first quarter of 2023, 20 hedge funds tracked by Insider Monkey were long Ardelyx, Inc. (NASDAQ:ARDX ...

Ardelyx, Inc. Common Stock (ARDX) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets.Real time Ardelyx (ARDX) stock price quote, stock graph, news & analysis.

WALTHAM, Mass., Oct. 24, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class ...AzurRx, Inc. (NASDAQ:AZRX) said due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 9.09 million ...The put contract at the $4.00 strike price has a current bid of 15 cents. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $4.00, but will also ...Dec 1, 2023 · Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. From discovery through commercialization, all of us at Ardelyx ® are driven to advance patient care with targeted, first-in-class, novel mechanism therapies that address significant unmet medical needs. We developed a unique and innovative platform that enabled the discovery of new biological mechanisms and pathways to create targeted, first ... Ardelyx (NASDAQ:ARDX) is a biopharmaceutical innovator specializing in renal and cardiovascular care, driving novel therapeutic solutions forward.The stock has consistently shown a positive ...Xencor Inc. 18.74. +0.01. +0.05%. Get Ardelyx Inc (ARDX:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.Analysts' Revenue Estimates For Ardelyx, Inc. (NASDAQ:ARDX) Are Surging Higher Dec 02. Ardelyx Announces Launching of IBSRELA® Second Quarter of 2022 Dec 01. Insider notifies of intention to sell stock Nov 19. Third quarter 2021 earnings released: US$0.42 loss per share (vs US$0.20 loss in 3Q 2020)Force Index charts of Daily price volume action, Weekly price volume action, Monthly price volume action of Ardelyx, Inc. ARDX NASDAQ. Data to use: Daily ...

Ardelyx (NASDAQ:ARDX) is a biotechnology company that focuses on developing novel therapies for unmet medical needs. The company’s growth and potential breakthroughs in medical treatments could ...

Ardelyx Inc (NASDAQ:ARDX) 4.34 Delayed Data As of Nov 17 +0.305 / +7.57% Today’s Change 1.56 Today ||| 52-Week Range 5.13 +52.11% Year-to-Date Quote Profile News …

Ardelyx, Inc. Common Stock (ARDX) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets. Ardelyx Inc (NASDAQ: ARDX) Ardelyx is a biotech penny stock which already has a successful product on the market . Ibsrela (tenapanor) is a drug that was introduced by the company in March 2022. It is used …AAPL. 189.69. -0.01%. 49.41M. View today's Ardelyx Inc stock price and latest ARDX news and analysis. Create real-time notifications to follow any changes in the live stock price.NASDAQ: ARDX. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Ardelyx Inc stocks or shares into any …ARDX ARDX AFTER HOURS QUOTE ARDX LATEST AFTER HOURS TRADES. ... Add symbols now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing stocks, funds and ETFs, ... Ardelyx (NASDAQ:ARDX), a biotech innovator, is arguably one of the best picks among penny stocks to buy. Its powerful portfolio, featuring IBSRELA for IBS-C and XPHOZAH for chronic kidney disease ...Hycroft Mining Holding Corporation Class A Common Stock (HYMC) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.25 thg 8, 2023 ... Cantor Fitzgerald, by way of analyst Louise Chen, upgraded Ardelyx to “overweight” in light of a very strong potential win. The analysts expect ...WALTHAM, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...The chain sheet shows the price, volume and open interest for each option strike price and expiration month. Nasdaq provides call and put options information of stocks. Financial analysts and ...Title. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result ...

NasdaqGM:ARDX Insider Trading Volume June 12th 2021 Ardelyx is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.Find the latest Insider Activity data for Ardelyx, Inc. Common Stock (ARDX) at Nasdaq.com. Nov 29, 2023 · See the latest Ardelyx Inc stock price (ARDX:XNAS), related news, valuation, dividends and more to help you make your investing decisions. Instagram:https://instagram. fabrikalarinasdaq mrnabac stock projectionsapextradingfunding Ardelyx (NASDAQ:ARDX) is a great speculative biotech play to look into. Why is that? That's because despite its potential with two drugs in the pipeline, the stock is still trading with a very low ... options trade alertsmsci acwi etf Aug 31, 2023 · Fintel reports that on September 12, 2023, HC Wainwright & Co. reiterated coverage of Ardelyx (NASDAQ:ARDX) with a Buy recommendation. Analyst Price Forecast Suggests 77.74% Upside. As of August ... charles schwab stock quote The put contract at the $4.00 strike price has a current bid of 15 cents. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $4.00, but will also ...After Hours Volume: 64.24K. Close. Chg. Chg %. $4.3300. 0.3000. 7.44%. Ardelyx Inc. advanced stock charts by MarketWatch. View ARDX historial stock data and compare to other stocks and exchanges.FREMONT, Calif. and WALTHAM, Mass., July 29, 2021 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases, today announced that it has …